This is a Non-interventional, Prospective, Multicenter Study Conducted in France. The Primary Objective of This Study is to Describe the Quality of Life of MS Patients After Initiation of Treatment With Ofatumumab.
Latest Information Update: 25 Dec 2025
At a glance
- Drugs Ofatumumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms SEPROS
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 22 Dec 2025 Status changed from recruiting to active, no longer recruiting.
- 14 Jan 2025 Planned End Date changed from 31 Jan 2026 to 31 Jul 2026.
- 14 Jan 2025 Planned primary completion date changed from 31 Jan 2026 to 31 Jul 2026.